CPT code 83037: A1c test, FDA-cleared home-use device2026 Medicare lab fee · Clinical Laboratory Fee Schedule
Hemoglobin A1c testing with an FDA-cleared home-use device is reported to assess longer-term glycemic control in diabetes care.
Medicare pays $9.71 for 83037 under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$9.71
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2020
- Unchanged
- QW · CLIA-waived test
- $9.71
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 8 sections
What 83037 covers
Code 83037 identifies hemoglobin A1c testing performed with a device cleared by FDA for home use. A1c reflects longer-term glycemic control and is used in diabetes management. Medicare utilization is reported in office settings, making this a point-of-care service commonly encountered in physician practices. The distinguishing feature is the device, rather than a separate clinical purpose from other A1c testing.
Report 83037 for testing performed with the qualifying device. CMS lists modifier QW for the CLIA-waived version; sites holding a CLIA certificate of waiver may perform that version. Medicare pays the test only through the CLFS. The 2026 national CLFS amount is $9.71, unchanged from 2020 through 2026. The same amount applies across states, localities, and office and facility settings.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 83037
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 83037. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Excluded from the physician fee schedule
The physician fee schedule lists 83037 with status X (excluded by statute), so the test itself is paid only from the CLFS.
CLIA-waived version (QW)
CMS also lists 83037 with modifier QW, the version labs holding a CLIA certificate of waiver bill. It pays $9.71.
83037 on the lab fee schedule since 2020
83037 · CLFS 2026 Q4 (current)
$9.71
Unchanged since Jan 1, 2020
27 quarterly CLFS releases on file, first CLFS 2020 Q1. A code missing from a quarter wasn’t on that release.
83037 compared with similar tests
- 83036A1c testLaboratory assay$9.71
- Both codes report A1c testing. Choose 83037 when the test uses a device cleared by FDA for home use; 83036 does not specify that device distinction.
- 83020Hemoglobin electrophoresisFractionation by electrophoresis$12.87
- 83020 evaluates hemoglobin by electrophoresis; 83037 measures A1c with a device cleared by FDA for home use.
- 83021Hemoglobin analysisChromatography-based fractionation$18.06
- 83021 evaluates hemoglobin by chromatography. Use 83037 for A1c testing with the specified home-use device.
83037 billing questions
How is 83037 different from 83036?
Use 83037 when A1c is measured with a device cleared by FDA for home use. Code 83036 is the nearby A1c code without this device-specific distinction.
When should modifier QW be reported?
Use QW for the CLIA-waived version when the testing site holds a CLIA certificate of waiver and performs the waived test.
Does Medicare pay 83037 under the physician fee schedule?
No. Medicare pays 83037 through the CLFS at one national amount that applies across localities and settings.
What distinguishes the device reported with 83037?
The test uses a device cleared by FDA for home use. That device characteristic distinguishes 83037 from the general A1c code 83036.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 83037 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist